Theriva Biologics, Inc.
TOVXDrugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Q3 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
VCN-01 oncolytic adenovirus (zabilugene almadenorepvec)
Pancreas Cancer, Metastatic
Period 1 - Treatment Sequence AB
Healthy Volunteers
SYN-004
Healthy Volunteers With Ileostomy
SYN-010
Irritable Bowel Syndrome With Constipation (IBS-C)
SYN-010 21 mg
Irritable Bowel Syndrome With Constipation (IBS-C)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) | Phase 2 | Pancreas Cancer, Metastatic | - | - |
Period 1 - Treatment Sequence AB | Phase 2 | Healthy Volunteers | - | - |
SYN-004 | Phase 2 | Healthy Volunteers With Ileostomy | - | - |
SYN-010 | Phase 2 | Irritable Bowel Syndrome With Constipation (IBS-C) | - | - |
SYN-010 21 mg | Phase 2 | Irritable Bowel Syndrome With Constipation (IBS-C) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Theriva Biologics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Theriva Biologics, Inc.'s (TOVX) pipeline across Phase 2. Its lead program is VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Theriva Biologics, Inc.'s next FDA catalyst?→
Theriva Biologics, Inc.'s (TOVX) next tracked catalyst is a Phase 2 expected August 1, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TOVX biotech catalysts?→
Add TOVX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Theriva Biologics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.